Clinical study on hybrid bioartificial liver supporting system for acute on chronic liver failure patients.
- Author:
Shao-Li YOU
1
;
Hong-Ling LIU
;
Yi-Hui RONG
;
Bing ZHU
;
Wan-Shu LIU
;
Pan-Yong MAO
;
Shao-Jie XIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Bioreactors; End Stage Liver Disease; therapy; Female; Hep G2 Cells; Humans; Liver Failure, Acute; therapy; Liver, Artificial; adverse effects; utilization; Male; Middle Aged; Treatment Outcome
- From: Chinese Journal of Experimental and Clinical Virology 2011;25(5):387-389
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo construct an hybrid bioartificial liver supporting system, and observe its effectiveness and safety on patients with acute on chronic liver failure.
METHODSHybrid bioartificial liver supporting system (HBALSS) was constructed using bioreactor with HepG2 cells transfected with human augmenter of liver regeneration (hALR) gene. 12 acute on chronic liver failure patients were divided into 2 groups randomly. The treatment group was treated with the hybrid bioartificial liver support system. The group underwent plasma exchange was used as control.
RESULTSIn the treatment group, four patients recovered, one patient died of hepatic encephalopathy, one patient died of hepatorenal syndrome, one patient recovered, but died of gastrointestnal bleeding after 1 year. In control group, two patients recovered, one patient underwent orthotropic liver transplantation, and three patients died of liver failure.
CONCLUSIONThe hybrid bioartificial liver supporting system with HepG2 cell line was established successfully and have certain safety and effectiveness on acute on chronic liver failure patients.
